ArticleLeukemia2017
NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.
Open access · hybridAbstract readLetter
In one paragraph
Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.Haematologica · 2024Article
- Investigation on the molecular mechanism of SPA interference with osteogenic differentiation of bone marrow mesenchymal stem cells.Scientific reports · 2024Article
- CRIP1 involves the pathogenesis of multiple myeloma via dual-regulation of proteasome and autophagy.EBioMedicine · 2024Article
- NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.Clinical and experimental medicine · 2023Article
- Exosome miRNAs profiling in serum and prognostic evaluation in patients with multiple myeloma.Blood science (Baltimore, Md.) · 2023Article
- [Establishment and comparison of three human multiple myeloma cell line transplantation models in mice].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.Cell death & disease · 2022Article
- Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.Molecules (Basel, Switzerland) · 2022Review
- lncRNA SNHG15 as a ceRNA modulates Osteoclast Differentiation, Proliferation, and Metastasis by Sponging miR-381-3p/NEK2 Axis.Journal of immunology research · 2022Article
- Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma.Frontiers in immunology · 2022Article
- TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.The Journal of clinical investigation · 2021Article
- Review
- Therapeutic effects of oligo-single-stranded DNA mimicking of hsa-miR-15a-5p on multiple myeloma.Cancer gene therapy · 2020Article
- Checking NEKs: Overcoming a Bottleneck in Human Diseases.Molecules (Basel, Switzerland) · 2020Review
- Non-Anticoagulant Heparins as Heparanase Inhibitors.Advances in experimental medicine and biology · 2020Review
- NIMA-related kinase 2 overexpression is associated with poor survival in cancer patients: a systematic review and meta-analysis.Cancer management and research · 2019Article
- Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity.Molecules (Basel, Switzerland) · 2018Review
- TRPV2-induced CaCell communication and signaling : CCS · 2018Article
- Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.The Journal of clinical investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
M HaoState Key Laboratory of Experimental Hematology, Institute of Hematology &Blood Diseases Hospital, Chinese Academy of Medical Science &Peking Union Medical College, Tianjin, China.
R Franqui-MachinDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
H XuDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
J ShaughnessyDepartment of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
B BarlogieDepartment of Medicine, Mount Sinai School of Medicine, New York, NY, USA.
D RoodmanDepartment of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
D E QuelleDepartment of Pharmacology, University of Iowa, Iowa City, IA, USA.
S JanzDepartment of Pathology, The University of Iowa Roy J and Lucille A Carver College of Medicine, Iowa City, IA, USA.
M H TomassonDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
R D SandersonDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
L QiuState Key Laboratory of Experimental Hematology, Institute of Hematology &Blood Diseases Hospital, Chinese Academy of Medical Science &Peking Union Medical College, Tianjin, China.
I FrechDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
G TricotDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
F ZhanDivision of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
University of Iowa · USIcahn School of Medicine at Mount Sinai · USIndiana University – Purdue University Indianapolis · USInstitute of Hematology & Blood Diseases Hospital · CNUniversity of Alabama at Birmingham · US
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Mark E Burkard · 2000 to 2026
$70.0MDefining genetic pathways of plasma-cell neoplasiaR01CA151354 · NCI · UNIVERSITY OF IOWA · PI JANZ, SIEGFRIED · 2010 to 2022
$3.9MHeparanase Regulation of Myeloma Metastasis: Mechanism and TherapyR01CA138340 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERSON, RALPH D · 2009 to 2018
$3.3MNEK2 Over-expression Causes Drug Resistance in MyelomaR01CA152105 · NCI · UNIVERSITY OF UTAH · PI ZHAN, FENGHUANG · 2010 to 2014
$1.5MRetinoid Based Treatment Approaches to Target the Myeloma Stem CellR21CA143887 · NCI · UNIVERSITY OF UTAH · PI ZHAN, FENGHUANG · 2010 to 2011
$354kRole of Microenvironmental-Derived AXII in Myeloma Bone DiseaseI01CX000623 · VA · VETERANS HEALTH ADMINISTRATION · PI Attaya Suvannasankha · 2013 to 2026
–CSRD VA I01 CX000623NCI NIH HHS R01 CA138340NCI NIH HHS R01 CA151354NCI NIH HHS R01 CA152105NCI NIH HHS R21 CA143887
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bone and BonesCell DifferentiationGlucuronidaseHeparanaseHumansMultiple MyelomaNIMA-Related KinasesOsteoclastsGlucuronidaseHeparanaseNEK2 protein, humanNIMA-Related Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.